{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T19:57:49Z","timestamp":1781639869297,"version":"3.54.5"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005378","name":"Hacettepe University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005378","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Puberty poses challenges for the management of congenital adrenal hyperplasia (CAH) due to changes in the endocrine milieu and non-compliance with treatment. Uncontrolled hyperandrogenemia is a significant problem, especially for CAH patients in this age group. Along with the attainment of final height, a therapeutic window emerges for employing more potent glucocorticoids (GCs) to improve disease management in the pediatric age group. Dexamethasone (Dex) is a long-acting and more potent GC, and offers a convenient dosing schedule for patients. In this study, we aimed to evaluate the efficacy of Dex treatment on biochemical and clinical hyperandrogenemia in patients with inadequately controlled CAH.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Children with CAH who had persistent biochemical\/clinical hyperandrogenemia despite recommended hydrocortisone dosing were included in the study at a single institution within the past 20 years. Participants were switched to Dex therapy at or near final height. Clinical and laboratory data and treatment outcomes for all participants were retrospectively evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Thirty-two patients (karyotype 46,XX in 18\/32, 46,XY in 14\/32) with a mean age of 15.5\u2009\u00b1\u20092 years were included in the study. 3 of 46,XX cases were male-reared (M\n                      <jats:sup>R<\/jats:sup>\n                      ), and so a total of 17\/32 (53%) of the patients were M\n                      <jats:sup>R<\/jats:sup>\n                      , and 15\/32 (47%) were female-reared (F\n                      <jats:sup>R<\/jats:sup>\n                      ). Following the transition to Dex therapy, both 17-hydroxyprogesterone (17OHP) (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01) and 1,4-delta-androstenedione (A4) (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01) levels showed a significant decrease after 6\u201312 months in all patients. In F\n                      <jats:sup>R<\/jats:sup>\n                      patients, puberty progressed in 5\/5, menstrual regularity improved in 3\/5, and hirsutism improved in 3\/7. In M\n                      <jats:sup>R<\/jats:sup>\n                      patients, A4\/testosterone ratio decreased in 10\/10, testis volumes increased in 7\/8. While there was no change in BMI z-score during treatment in M\n                      <jats:sup>R<\/jats:sup>\n                      patients, an increase in BMI z-score was observed only during the first six months in F\n                      <jats:sup>R<\/jats:sup>\n                      patients (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.014).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Dex effectively suppresses adrenal androgens and can be used to restore the hypothalamo-pituitary-gonad axis in children with CAH who have uncontrolled hyperandrogenemia and have reached final height. To minimize weight gain and metabolic side effects, treatment should be initiated at a low dose and androgen levels should be monitored without delay.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12020-026-04577-9","type":"journal-article","created":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T01:57:44Z","timestamp":1773107864000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Dexamethasone therapy in adolescents with inadequately controlled congenital adrenal hyperplasia: effects on hormonal Suppression, Puberty, and gonadal outcomes"],"prefix":"10.1007","volume":"91","author":[{"given":"N. Berna","family":"\u00c7elik Erta\u015f","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burcu","family":"\u015eenkalfa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Do\u011fu\u015f","family":"Vurall\u0131","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z. Alev","family":"\u00d6z\u00f6n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Nazl\u0131","family":"G\u00f6n\u00e7","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,10]]},"reference":[{"issue":"11","key":"4577_CR1","doi-asserted-by":"publisher","first-page":"5110","DOI":"10.1210\/jc.2010-0917","volume":"95","author":"W Arlt","year":"2010","unstructured":"W. Arlt, D.S. Willis, S.H. Wild, N. Krone, E.J. Doherty, S. Hahner et al., Health status of adults with congenital adrenal hyperplasia: a cohort study of 203 patients. J. Clin. Endocrinol. Metab. 95(11), 5110\u20135121 (2010)","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"12","key":"4577_CR2","doi-asserted-by":"publisher","first-page":"4429","DOI":"10.1210\/jc.2012-2102","volume":"97","author":"GP Finkielstain","year":"2012","unstructured":"G.P. Finkielstain, M.S. Kim, N. Sinaii, M. Nishitani, Van C. Ryzin, S.C. Hill et al., Clinical characteristics of a cohort of 244 patients with congenital adrenal hyperplasia. J. Clin. Endocrinol. Metab. 97(12), 4429\u20134438 (2012)","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"4","key":"4577_CR3","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/S2213-8587(13)70138-4","volume":"1","author":"DP Merke","year":"2013","unstructured":"D.P. Merke, D.P. Poppas, Management of adolescents with congenital adrenal hyperplasia. Lancet Diabetes Endocrinol. 1(4), 341\u2013352 (2013)","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"4","key":"4577_CR4","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1111\/cen.14992","volume":"101","author":"C Balagamage","year":"2024","unstructured":"C. Balagamage, A. Arshad, Y.S. Elhassan, W. Ben Said, R.E. Krone, H. Gleeson et al., Management aspects of congenital adrenal hyperplasia during adolescence and transition to adult care. Clin. Endocrinol. (Oxf). 101(4), 332\u2013345 (2024)","journal-title":"Clin. Endocrinol. (Oxf)"},{"issue":"4","key":"4577_CR5","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1136\/adc.86.4.266","volume":"86","author":"E Charmandari","year":"2002","unstructured":"E. Charmandari, C.G. Brook, P.C. Hindmarsh, Why is management of patients with classical congenital adrenal hyperplasia more difficult at puberty? Arch. Dis. Child. 86(4), 266\u2013269 (2002)","journal-title":"Arch. Dis. Child."},{"issue":"1","key":"4577_CR6","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1210\/jcem-72-1-39","volume":"72","author":"NV Esteban","year":"1991","unstructured":"N.V. Esteban, T. Loughlin, A.L. Yergey, J.K. Zawadzki, J.D. Booth, J.C. Winterer et al., Daily cortisol production rate in man determined by stable isotope dilution\/mass spectrometry. J. Clin. Endocrinol. Metab. 72(1), 39\u201345 (1991)","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"Suppl 3","key":"4577_CR7","doi-asserted-by":"publisher","first-page":"U77","DOI":"10.1530\/eje.0.151u077","volume":"151","author":"E Charmandari","year":"2004","unstructured":"E. Charmandari, C.G. Brook, P.C. Hindmarsh, Classic congenital adrenal hyperplasia and puberty. Eur. J. Endocrinol. 151(Suppl 3), U77\u201382 (2004)","journal-title":"Eur. J. Endocrinol."},{"issue":"11","key":"4577_CR8","first-page":"3892","volume":"81","author":"D l\u2019Allemand","year":"1996","unstructured":"D. l\u2019Allemand, A. Penhoat, M.C. Lebrethon, R. Ard\u00e8vol, V. Baehr, W. Oelkers et al., Insulin-like growth factors enhance steroidogenic enzyme and Corticotropin receptor messenger ribonucleic acid levels and Corticotropin steroidogenic responsiveness in cultured human adrenocortical cells. J. Clin. Endocrinol. Metab. 81(11), 3892\u20133897 (1996)","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"2","key":"4577_CR9","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/S0039-128X(96)00223-1","volume":"62","author":"SB Kristiansen","year":"1997","unstructured":"S.B. Kristiansen, A. Endoh, P.R. Casson, J.E. Buster, P.J. Hornsby, Induction of steroidogenic enzyme genes by insulin and IGF-I in cultured adult human adrenocortical cells. Steroids. 62(2), 258\u2013265 (1997)","journal-title":"Steroids"},{"issue":"1","key":"4577_CR10","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1093\/pch\/13.1.19","volume":"13","author":"D Taddeo","year":"2008","unstructured":"D. Taddeo, M. Egedy, J.Y. Frappier, Adherence to treatment in adolescents. Paediatr. Child. Health. 13(1), 19\u201324 (2008)","journal-title":"Paediatr. Child. Health"},{"key":"4577_CR11","doi-asserted-by":"publisher","first-page":"212","DOI":"10.3389\/fendo.2019.00212","volume":"10","author":"N Improda","year":"2019","unstructured":"N. Improda, F. Barbieri, G.P. Ciccarelli, D. Capalbo, M. Salerno, Cardiovascular health in children and adolescents with congenital adrenal hyperplasia due to 21-Hydroxilase deficiency. Front. Endocrinol. (Lausanne). 10, 212 (2019)","journal-title":"Front. Endocrinol. (Lausanne)"},{"issue":"6","key":"4577_CR12","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1136\/archdischild-2016-311910","volume":"102","author":"CF Mooij","year":"2017","unstructured":"C.F. Mooij, E.A. Webb, H.L. van der Claahsen, N. Krone, Cardiovascular health, growth and gonadal function in children and adolescents with congenital adrenal hyperplasia. Arch. Dis. Child. 102(6), 578\u2013584 (2017)","journal-title":"Arch. Dis. Child."},{"key":"4577_CR13","doi-asserted-by":"crossref","unstructured":"A. Dauber, H.A. Feldman, J.A. Majzoub, Nocturnal Dexamethasone versus Hydrocortisone for the Treatment of Children with Congenital Adrenal Hyperplasia. Int J Pediatr Endocrinol. 2010;2010","DOI":"10.1186\/1687-9856-2010-347636"},{"issue":"2","key":"4577_CR14","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1111\/cen.12045","volume":"78","author":"TS Han","year":"2013","unstructured":"T.S. Han, R.H. Stimson, D.A. Rees, N. Krone, D.S. Willis, G.S. Conway et al., Glucocorticoid treatment regimen and health outcomes in adults with congenital adrenal hyperplasia. Clin. Endocrinol. (Oxf). 78(2), 197\u2013203 (2013)","journal-title":"Clin. Endocrinol. (Oxf)"},{"issue":"6","key":"4577_CR15","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1210\/js.2019-00136","volume":"3","author":"E Whittle","year":"2019","unstructured":"E. Whittle, H. Falhammar, Glucocorticoid regimens in the treatment of congenital adrenal hyperplasia: A systematic review and Meta-Analysis. J. Endocr. Soc. 3(6), 1227\u20131245 (2019)","journal-title":"J. Endocr. Soc."},{"issue":"3","key":"4577_CR16","doi-asserted-by":"crossref","first-page":"e14657","DOI":"10.5812\/ijem.14657","volume":"12","author":"D van der Kaay","year":"2014","unstructured":"van der D. Kaay, van den E. Akker, Ultralow-dose dexamethasone to preserve endogenous cortisol stress response in nonclassical congenital adrenal hyperplasia: A new promising treatment. Int. J. Endocrinol. Metab. 12(3), e14657 (2014)","journal-title":"Int. J. Endocrinol. Metab."},{"key":"4577_CR17","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13633-016-0035-5","volume":"2016","author":"TD Nebesio","year":"2016","unstructured":"T.D. Nebesio, J.L. Renbarger, Z.M. Nabhan, S.E. Ross, J.E. Slaven, L. Li et al., Differential effects of hydrocortisone, prednisone, and dexamethasone on hormonal and Pharmacokinetic profiles: a pilot study in children with congenital adrenal hyperplasia. Int. J. Pediatr. Endocrinol. 2016, 17 (2016)","journal-title":"Int. J. Pediatr. Endocrinol."},{"issue":"6","key":"4577_CR18","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1210\/jcem-47-6-1208","volume":"47","author":"GE Richards","year":"1978","unstructured":"G.E. Richards, M.M. Grumbach, S.L. Kaplan, F.A. Conte, The effect of long acting glucocorticoids on menstrual abnormalities in patients with virilizing congenital adrenal hyperplasia. J. Clin. Endocrinol. Metab. 47(6), 1208\u20131215 (1978)","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1","key":"4577_CR19","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/S0197-0070(81)80081-2","volume":"2","author":"AB Granoff","year":"1981","unstructured":"A.B. Granoff, Treatment of menstrual irregularities with dexamethasone in congenital adrenal hyperplasia. J. Adolesc. Health Care. 2(1), 23\u201327 (1981)","journal-title":"J. Adolesc. Health Care"},{"issue":"2","key":"4577_CR20","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1159\/000179489","volume":"16","author":"IA Hughes","year":"1982","unstructured":"I.A. Hughes, G.F. Read, Menarche and subsequent ovarian function in girls with congenital adrenal hyperplasia. Horm. Res. 16(2), 100\u2013106 (1982)","journal-title":"Horm. Res."},{"issue":"11","key":"4577_CR21","doi-asserted-by":"publisher","first-page":"4043","DOI":"10.1210\/jc.2018-01865","volume":"103","author":"PW Speiser","year":"2018","unstructured":"P.W. Speiser, W. Arlt, R.J. Auchus, L.S. Baskin, G.S. Conway, D.P. Merke et al., Congenital adrenal hyperplasia due to steroid 21-Hydroxylase deficiency: an endocrine Society* clinical practice guideline. J. Clin. Endocrinol. Metabolism. 103(11), 4043\u20134088 (2018)","journal-title":"J. Clin. Endocrinol. Metabolism"},{"issue":"8","key":"4577_CR22","doi-asserted-by":"publisher","first-page":"2763","DOI":"10.1210\/jc.2014-1258","volume":"99","author":"RJ Auchus","year":"2014","unstructured":"R.J. Auchus, E.O. Buschur, A.Y. Chang, G.D. Hammer, C. Ramm, D. Madrigal et al., Abiraterone acetate to lower androgens in women with classic 21-hydroxylase deficiency. J. Clin. Endocrinol. Metab. 99(8), 2763\u20132770 (2014)","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"2","key":"4577_CR23","doi-asserted-by":"publisher","first-page":"94","DOI":"10.4274\/jcrpe.563","volume":"4","author":"ED \u00c7akir","year":"2012","unstructured":"E.D. \u00c7akir, F.S. Mutlu, E. Eren, A.O. Pa\u015fa, H. Sa\u011flam, O. Tarim, Testicular adrenal rest tumors in patients with congenital adrenal hyperplasia. J. Clin. Res. Pediatr. Endocrinol. 4(2), 94\u2013100 (2012)","journal-title":"J. Clin. Res. Pediatr. Endocrinol."},{"key":"4577_CR24","unstructured":"B.P. Schimmer, J.W. Funder, Adrenocorticotropic Hormone, adrenal Steroids, and the adrenal cortex. In : L.L. Brunton, R. Hilal-Dandan, B.C. Knollmann (eds.) Goodman & Gilman\u2019s: the Pharmacological Basis of therapeutics, 13 edition, pp 845-861. McGraw-Hill Education, New York, NY (2017)."},{"issue":"3","key":"4577_CR25","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1136\/adc.51.3.170","volume":"51","author":"JM Tanner","year":"1976","unstructured":"J.M. Tanner, R.H. Whitehouse, Clinical longitudinal standards for height, weight, height velocity, weight velocity, and stages of puberty. Arch. Dis. Child. 51(3), 170\u2013179 (1976)","journal-title":"Arch. Dis. Child."},{"key":"4577_CR26","first-page":"574","volume-title":"Williams Textbook of Endocrinology","author":"SE Bulun","year":"2020","unstructured":"S.E. Bulun, Physiology and pathology of the female reproductive axis, in Williams Textbook of Endocrinology, 14th edn., ed. by S.A.R. Melmed, A.B. Goldfine, R.J. Koenig, C.J. Rosen (Elsevier, Philadelphia, 2020), pp. 574\u2013783","edition":"14"},{"key":"4577_CR27","unstructured":"Centers for Disease Control and Prevention, Growth Charts. [Available from: http:\/\/www.cdc.gov\/growthcharts"},{"key":"4577_CR28","doi-asserted-by":"crossref","unstructured":"J.T. Flynn, D.C. Kaelber, C.M. Baker-Smith et al., Subcommittee on Screening and Management of High Blood Pressure in Children. Clinical Practice Guideline for Screening and Management of High Blood Pressure in Children and Adolescents. Pediatrics. 2017;140(3):e20171904. Pediatrics. 2018;142(3)","DOI":"10.1542\/peds.2018-1739"},{"issue":"5","key":"4577_CR29","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1542\/peds.2006-2481","volume":"118","author":"A Diaz","year":"2006","unstructured":"A. Diaz, M.R. Laufer, L.L. Breech, Menstruation in girls and adolescents: using the menstrual cycle as a vital sign. Pediatrics. 118(5), 2245\u20132250 (2006)","journal-title":"Pediatrics"},{"issue":"6","key":"4577_CR30","doi-asserted-by":"publisher","first-page":"388","DOI":"10.3949\/ccjm.77a.08079","volume":"77","author":"S Harrison","year":"2010","unstructured":"S. Harrison, N. Somani, W.F. Bergfeld, Update on the management of hirsutism. Cleve Clin. J. Med. 77(6), 388\u2013398 (2010)","journal-title":"Cleve Clin. J. Med."},{"key":"4577_CR31","doi-asserted-by":"publisher","first-page":"469289","DOI":"10.1155\/2014\/469289","volume":"2014","author":"B Dudzi\u0144ska","year":"2014","unstructured":"B. Dudzi\u0144ska, J. Leubner, M. Ventz, M. Quinkler, Sexual well-being in adult male patients with congenital adrenal hyperplasia. Int. J. Endocrinol. 2014, 469289 (2014)","journal-title":"Int. J. Endocrinol."},{"issue":"3","key":"4577_CR32","doi-asserted-by":"publisher","first-page":"705e5","DOI":"10.1016\/j.fertnstert.2006.11.148","volume":"88","author":"HL Claahsen-van der Grinten","year":"2007","unstructured":"H.L. Claahsen-van der Grinten, B.J. Otten, F.C. Sweep, A.R. Hermus, Repeated successful induction of fertility after replacing hydrocortisone with dexamethasone in a patient with congenital adrenal hyperplasia and testicular adrenal rest tumors. Fertil. Steril. 88(3), 705e5\u2013705e8 (2007)","journal-title":"Fertil. Steril."},{"issue":"2","key":"4577_CR33","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1136\/adc.87.2.139","volume":"87","author":"HJ Van der Kamp","year":"2002","unstructured":"Van der H.J. Kamp, B.J. Otten, N. Buitenweg, De S.M. Muinck Keizer-Schrama, W. Oostdijk, M. Jansen et al., Longitudinal analysis of growth and puberty in 21-hydroxylase deficiency patients. Arch. Dis. Child. 87(2), 139\u2013144 (2002)","journal-title":"Arch. Dis. Child."},{"issue":"2","key":"4577_CR34","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1067\/mpd.2002.126601","volume":"141","author":"S Muirhead","year":"2002","unstructured":"S. Muirhead, E.A. Sellers, H. Guyda, Indicators of adult height outcome in classical 21-hydroxylase deficiency congenital adrenal hyperplasia. J. Pediatr. 141(2), 247\u2013252 (2002)","journal-title":"J. Pediatr."},{"issue":"10","key":"4577_CR35","doi-asserted-by":"publisher","first-page":"3882","DOI":"10.1210\/jc.2009-0942","volume":"94","author":"W Bonfig","year":"2009","unstructured":"W. Bonfig, S.B. Pozza, H. Schmidt, P. Pagel, D. Knorr, H.P. Schwarz, Hydrocortisone dosing during puberty in patients with classical congenital adrenal hyperplasia: an evidence-based recommendation. J. Clin. Endocrinol. Metab. 94(10), 3882\u20133888 (2009)","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"6","key":"4577_CR36","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1159\/000333696","volume":"76","author":"TM V\u00f6lkl","year":"2011","unstructured":"T.M. V\u00f6lkl, L. \u00d6hl, M. Rauh, C. Sch\u00f6fl, H.G. D\u00f6rr, Adrenarche and puberty in children with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Horm. Res. Paediatr. 76(6), 400\u2013410 (2011)","journal-title":"Horm. Res. Paediatr."},{"issue":"Supplement1","key":"4577_CR37","doi-asserted-by":"publisher","first-page":"S25","DOI":"10.1210\/clinem\/dgae718","volume":"110","author":"HL Claahsen-van der Grinten","year":"2025","unstructured":"H.L. Claahsen-van der Grinten, B.P.H. Adriaansen, H. Falhammar, Challenges in adolescent and adult males with classic congenital adrenal hyperplasia due to 21-Hydroxylase deficiency. J. Clin. Endocrinol. Metab. 110(Supplement1), S25\u2013s36 (2025)","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"3","key":"4577_CR38","doi-asserted-by":"publisher","first-page":"R85","DOI":"10.1530\/EJE-20-1093","volume":"184","author":"HL Claahsen-van der Grinten","year":"2021","unstructured":"H.L. Claahsen-van der Grinten, N. Stikkelbroeck, H. Falhammar, N. Reisch, MANAGEMENT OF ENDOCRINE DISEASE: gonadal dysfunction in congenital adrenal hyperplasia. Eur. J. Endocrinol. 184(3), R85\u2013r97 (2021)","journal-title":"Eur. J. Endocrinol."},{"issue":"7","key":"4577_CR39","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s13312-022-2555-9","volume":"59","author":"J Kaur","year":"2022","unstructured":"J. Kaur, M. Singla, A. Bhansali, S. Bhadada, R. Walia, Anthropometric and pubertal outcomes in girls with classical congenital adrenal hyperplasia. Indian Pediatr. 59(7), 535\u2013538 (2022)","journal-title":"Indian Pediatr."},{"issue":"4","key":"4577_CR40","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1016\/S0015-0282(03)01006-9","volume":"80","author":"NM Stikkelbroeck","year":"2003","unstructured":"N.M. Stikkelbroeck, C.G. Sweep, D.D. Braat, A.R. Hermus, B.J. Otten, Monitoring of menstrual cycles, ovulation, and adrenal suppression by saliva sampling in female patients with 21-hydroxylase deficiency. Fertil. Steril. 80(4), 1030\u20131036 (2003)","journal-title":"Fertil. Steril."},{"issue":"3","key":"4577_CR41","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1111\/j.1365-2265.1995.tb02034.x","volume":"43","author":"DJ Holmes-Walker","year":"1995","unstructured":"D.J. Holmes-Walker, G.S. Conway, J.W. Honour, G. Rumsby, H.S. Jacobs, Menstrual disturbance and hypersecretion of progesterone in women with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Clin. Endocrinol. (Oxf). 43(3), 291\u2013296 (1995)","journal-title":"Clin. Endocrinol. (Oxf)"},{"issue":"11","key":"4577_CR42","doi-asserted-by":"publisher","first-page":"4043","DOI":"10.1210\/jc.2018-01865","volume":"103","author":"PW Speiser","year":"2018","unstructured":"P.W. Speiser, W. Arlt, R.J. Auchus, L.S. Baskin, G.S. Conway, D.P. Merke et al., Congenital adrenal hyperplasia due to steroid 21-Hydroxylase deficiency: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 103(11), 4043\u20134088 (2018)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"4577_CR43","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.mce.2015.01.039","volume":"408","author":"RJ Auchus","year":"2015","unstructured":"R.J. Auchus, Management considerations for the adult with congenital adrenal hyperplasia. Mol. Cell. Endocrinol. 408, 190\u2013197 (2015)","journal-title":"Mol. Cell. Endocrinol."},{"issue":"Supplement1","key":"4577_CR44","doi-asserted-by":"publisher","first-page":"S37","DOI":"10.1210\/clinem\/dgae696","volume":"110","author":"H Engberg","year":"2025","unstructured":"H. Engberg, A. Nordenstr\u00f6m, A.L. Hirschberg, Clinical manifestations and challenges in adolescent and adult females with classic congenital adrenal hyperplasia due to 21-Hydroxylase deficiency. J. Clin. Endocrinol. Metabolism. 110(Supplement1), S37\u2013S45 (2025)","journal-title":"J. Clin. Endocrinol. Metabolism"},{"issue":"4","key":"4577_CR45","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1093\/ejendo\/lvad143","volume":"189","author":"MAM Schr\u00f6der","year":"2023","unstructured":"M.A.M. Schr\u00f6der, M. Neac\u015fu, B.P.H. Adriaansen, F. Sweep, S.F. Ahmed, S.R. Ali et al., Hormonal control during infancy and testicular adrenal rest tumor development in males with congenital adrenal hyperplasia: a retrospective multicenter cohort study. Eur. J. Endocrinol. 189(4), 460\u2013468 (2023)","journal-title":"Eur. J. Endocrinol."},{"issue":"4","key":"4577_CR46","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1159\/000365570","volume":"82","author":"HL Claahsen-van der Grinten","year":"2014","unstructured":"H.L. Claahsen-van der Grinten, F. Dehzad, K. Kamphuis-van Ulzen, de C.L. Korte, Increased prevalence of testicular adrenal rest tumours during adolescence in congenital adrenal hyperplasia. Horm. Res. Paediatr. 82(4), 238\u2013244 (2014)","journal-title":"Horm. Res. Paediatr."},{"issue":"5","key":"4577_CR47","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1111\/cen.13313","volume":"86","author":"K Sarafoglou","year":"2017","unstructured":"K. Sarafoglou, G.P. Forlenza, O. Yaw Addo, J. Kyllo, A. Lteif, P.C. Hindmarsh et al., Obesity in children with congenital adrenal hyperplasia in the Minnesota cohort: importance of adjusting body mass index for height-age. Clin. Endocrinol. (Oxf). 86(5), 708\u2013716 (2017)","journal-title":"Clin. Endocrinol. (Oxf)"},{"issue":"1","key":"4577_CR48","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1002\/acr.21785","volume":"65","author":"NJ Shiff","year":"2013","unstructured":"N.J. Shiff, R. Brant, J. Guzman, D.A. Cabral, A.M. Huber, P. Miettunen et al., Glucocorticoid-related changes in body mass index among children and adolescents with rheumatic diseases. Arthritis Care Res. (Hoboken). 65(1), 113\u2013121 (2013)","journal-title":"Arthritis Care Res. (Hoboken)"},{"issue":"8","key":"4577_CR49","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.biopsych.2007.04.013","volume":"62","author":"R Kumsta","year":"2007","unstructured":"R. Kumsta, S. Entringer, J.W. Koper, van E.F. Rossum, D.H. Hellhammer, S. W\u00fcst, Sex specific associations between common glucocorticoid receptor gene variants and hypothalamus-pituitary-adrenal axis responses to psychosocial stress. Biol. Psychiatry. 62(8), 863\u2013869 (2007)","journal-title":"Biol. Psychiatry"}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-026-04577-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-026-04577-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-026-04577-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T19:41:44Z","timestamp":1781638904000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-026-04577-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,10]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4577"],"URL":"https:\/\/doi.org\/10.1007\/s12020-026-04577-9","relation":{},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,10]]},"assertion":[{"value":"17 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}},{"value":"This study protocol was reviewed and approved by Hacettepe University Health Sciences Research Ethics Committee, approval number 2024\/14-25, project number: SBA 24\/887. Informed consent was waived due to the retrospective nature of the study (Hacettepe University Health Sciences Research Ethics Committee, approval number 2024\/14-25, project number: SBA 24\/887).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"109"}}